4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Hikma Pharmaceuticals PLC (HIK) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in London, United Kingdom with about 9,500 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, HIK reported $3.3B in revenue and $402M in net income.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $3.3B | $3.1B | $2.9B | $2.5B | — |
| Gross Profit | $1.4B | $1.4B | $1.4B | $1.2B | — |
| Operating Income (EBIT) | $633M | $612M | $610M | $482M | — |
| Net Income | $402M | $359M | $190M | $188M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | ($185M) | ($175M) | ($137M) | ($125M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $5.7B | $5.1B | $4.7B | $4.5B | — |
| Total Liabilities | $3.1B | $2.8B | $2.5B | $2.3B | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HIK viewer.
About TickerBase · Data methodology & sources · Privacy · Terms